Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...

The German pharmaceutical company is expected to post higher sales in its healthcare business on increased demand for bladder ...

Mavenclad hasn’t really got going yet in sales terms, bringing in a modest €90 million in 2018 from the 50 or so countries it has been approved in to date, albeit up from just €5 million in ...

Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...

In addition, some MS disease-modifying therapies come with cancer warnings. Cladribine (Mavenclad), for example, carries a ...

US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Blair’s MS is currently in remission. She exclusively told Us Weekly in August that she’s had “amazing” results with the medication Mavenclad. “It helped my movement and speech so much ...

Investing.com -- Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window People with MS had a 6% increased risk of developing any ...